Catalent acquires New Jersey cell therapy development and manufacturing facility
Catalent has acquired a commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, from Erytech Pharma for $44.5m.
Archives for April 25, 2022
Biogen withdraws EU marketing application for Aduhelm
Biogen has withdrawn its Marketing Authorization Application for Aduhelm (aducanumab) for the treatment of the early stages of Alzheimer’s disease in the EU.